Induction of immunological tolerance to transgene products

Brandon Wilder, David M. Markusic, Roland W. Herzog

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Gene transfer holds the possibility of correcting difficult or impossible to treat disorders, ranging from inherited monogenic diseases to graft rejection in transplant surgery. However, one barrier to success in gene therapy is the immune response to the protein encoded by the transgene. Because the transgene product is often missing in the patient, they will have developed lymphocytes capable of generating an immune response to the therapeutic protein, thereby rendering treatment ineffective. Thus, finding a way to induce tolerance to the gene product is the focus of a considerable amount of research. This research often relies heavily on delivery of the transgene to anatomical sites of the body that are naturally immune privileged or potentially immune suppressive, such as the liver, central nervous system, eyes, and hematopoietic cells. The benefits of tolerance induction by gene transfer are not limited for using gene therapy as a protein replacement strategy but can be extended to any situation where an immune response is unfavorable, such as autoimmune disease. This chapter focuses on the different strategies used to induce tolerance to transgene products along with the practical applications and limitations of those strategies based on the physiology of each anatomical site targeted.

Original languageEnglish (US)
Title of host publicationThe Immunological Barriers to Regenerative Medicine
PublisherSpringer New York
Pages297-311
Number of pages15
ISBN (Electronic)9781461454809
ISBN (Print)9781461454793
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Transgenes
Gene transfer
Gene therapy
Genetic Therapy
Transplants
Proteins
Lymphocytes
Physiology
Neurology
Genes
Grafts
Liver
Surgery
Graft Rejection
Research
Autoimmune Diseases
Central Nervous System
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Wilder, B., Markusic, D. M., & Herzog, R. W. (2013). Induction of immunological tolerance to transgene products. In The Immunological Barriers to Regenerative Medicine (pp. 297-311). Springer New York. https://doi.org/10.1007/978-1-4614-5480-9_15

Induction of immunological tolerance to transgene products. / Wilder, Brandon; Markusic, David M.; Herzog, Roland W.

The Immunological Barriers to Regenerative Medicine. Springer New York, 2013. p. 297-311.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wilder, B, Markusic, DM & Herzog, RW 2013, Induction of immunological tolerance to transgene products. in The Immunological Barriers to Regenerative Medicine. Springer New York, pp. 297-311. https://doi.org/10.1007/978-1-4614-5480-9_15
Wilder B, Markusic DM, Herzog RW. Induction of immunological tolerance to transgene products. In The Immunological Barriers to Regenerative Medicine. Springer New York. 2013. p. 297-311 https://doi.org/10.1007/978-1-4614-5480-9_15
Wilder, Brandon ; Markusic, David M. ; Herzog, Roland W. / Induction of immunological tolerance to transgene products. The Immunological Barriers to Regenerative Medicine. Springer New York, 2013. pp. 297-311
@inbook{86b6ca845c3c411e978ab6545601f4d5,
title = "Induction of immunological tolerance to transgene products",
abstract = "Gene transfer holds the possibility of correcting difficult or impossible to treat disorders, ranging from inherited monogenic diseases to graft rejection in transplant surgery. However, one barrier to success in gene therapy is the immune response to the protein encoded by the transgene. Because the transgene product is often missing in the patient, they will have developed lymphocytes capable of generating an immune response to the therapeutic protein, thereby rendering treatment ineffective. Thus, finding a way to induce tolerance to the gene product is the focus of a considerable amount of research. This research often relies heavily on delivery of the transgene to anatomical sites of the body that are naturally immune privileged or potentially immune suppressive, such as the liver, central nervous system, eyes, and hematopoietic cells. The benefits of tolerance induction by gene transfer are not limited for using gene therapy as a protein replacement strategy but can be extended to any situation where an immune response is unfavorable, such as autoimmune disease. This chapter focuses on the different strategies used to induce tolerance to transgene products along with the practical applications and limitations of those strategies based on the physiology of each anatomical site targeted.",
author = "Brandon Wilder and Markusic, {David M.} and Herzog, {Roland W.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-5480-9_15",
language = "English (US)",
isbn = "9781461454793",
pages = "297--311",
booktitle = "The Immunological Barriers to Regenerative Medicine",
publisher = "Springer New York",

}

TY - CHAP

T1 - Induction of immunological tolerance to transgene products

AU - Wilder, Brandon

AU - Markusic, David M.

AU - Herzog, Roland W.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Gene transfer holds the possibility of correcting difficult or impossible to treat disorders, ranging from inherited monogenic diseases to graft rejection in transplant surgery. However, one barrier to success in gene therapy is the immune response to the protein encoded by the transgene. Because the transgene product is often missing in the patient, they will have developed lymphocytes capable of generating an immune response to the therapeutic protein, thereby rendering treatment ineffective. Thus, finding a way to induce tolerance to the gene product is the focus of a considerable amount of research. This research often relies heavily on delivery of the transgene to anatomical sites of the body that are naturally immune privileged or potentially immune suppressive, such as the liver, central nervous system, eyes, and hematopoietic cells. The benefits of tolerance induction by gene transfer are not limited for using gene therapy as a protein replacement strategy but can be extended to any situation where an immune response is unfavorable, such as autoimmune disease. This chapter focuses on the different strategies used to induce tolerance to transgene products along with the practical applications and limitations of those strategies based on the physiology of each anatomical site targeted.

AB - Gene transfer holds the possibility of correcting difficult or impossible to treat disorders, ranging from inherited monogenic diseases to graft rejection in transplant surgery. However, one barrier to success in gene therapy is the immune response to the protein encoded by the transgene. Because the transgene product is often missing in the patient, they will have developed lymphocytes capable of generating an immune response to the therapeutic protein, thereby rendering treatment ineffective. Thus, finding a way to induce tolerance to the gene product is the focus of a considerable amount of research. This research often relies heavily on delivery of the transgene to anatomical sites of the body that are naturally immune privileged or potentially immune suppressive, such as the liver, central nervous system, eyes, and hematopoietic cells. The benefits of tolerance induction by gene transfer are not limited for using gene therapy as a protein replacement strategy but can be extended to any situation where an immune response is unfavorable, such as autoimmune disease. This chapter focuses on the different strategies used to induce tolerance to transgene products along with the practical applications and limitations of those strategies based on the physiology of each anatomical site targeted.

UR - http://www.scopus.com/inward/record.url?scp=85028505482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028505482&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-5480-9_15

DO - 10.1007/978-1-4614-5480-9_15

M3 - Chapter

SN - 9781461454793

SP - 297

EP - 311

BT - The Immunological Barriers to Regenerative Medicine

PB - Springer New York

ER -